Mersana Therapeutics, Inc. (MRSN) earnings
MRSN earnings moved a median of -0.76% by the close. Quarterly and annual MRSN reports and results, each read against the price at its own news timestamp. Back to the MRSN overview →
23 measured MRSN earnings events.
Where these MRSN earnings landedvs 23 measured MRSN earnings reactions
| Middle 50% of MRSN earnings reactions | -6.72% to +2.61% |
|---|---|
| Median reaction (to close) | -0.76% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 MRSN earnings events with a measured close landed between -6.72% and +2.61%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Mersana Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.40% | +2.61% | |
| Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results | Press release | +0.40% | +2.61% | |
| Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 | Press release | +0.59% | +1.29% | |
| Form 10-Q Mersana Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -6.43% | +21.61% | |
| Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results | Press release | -6.43% | +21.61% | |
| Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | Press release | +0.14% | -3.32% | |
| CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results | Press release | -6.00% | -13.98% | |
| Form 10-Q Mersana Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -6.00% | -13.98% | |
| Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results | Press release | -6.00% | -13.98% | |
| Form 10-K Mersana Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -6.46% | -10.11% | |
| Form 10-Q Mersana Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +2.26% | -0.76% | |
| Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results | Press release | +2.26% | -0.76% | |
| Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 | Press release | -1.42% | +10.38% | |
| Form 10-Q Mersana Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.96% | +0.00% | |
| Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results | Press release | +2.96% | +0.00% | |
| Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024 | Press release | -1.92% | -3.21% | |
| Form 10-Q Mersana Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.43% | -29.37% | |
| Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results | Press release | -1.43% | -29.37% | |
| Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 | Press release | -1.18% | -0.59% | |
| Form 10-K Mersana Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.11% | +20.05% | |
| Form 10-Q Mersana Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +2.92% | -2.19% | |
| Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results | Press release | +2.92% | -2.19% | |
| Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023 | Press release | +0.85% | +2.99% |
Keep exploring
More MRSN: analyst actions → · SEC filings → · MRSN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DOVA PHARMACEUTICALS (DOVA) | 251 | -0.10% | 46% |
| Krystal Biotech, Inc. (KRYS) | 251 | +0.05% | 52% |
| Soligenix, Inc. (SNGX) | 251 | -0.71% | 35% |
| Co-Diagnostics, Inc. (CODX) | 250 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.